Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Q BioMed Inc QBIO

Healthcare Biotechnology
Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated... see more

Recent & Breaking News (GREY:QBIO)

Q BioMed Inc. Provides Update to Shareholders

PR Newswire June 23, 2023

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe

PR Newswire April 14, 2023

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office

PR Newswire February 10, 2023

Q BIOMED ANNOUNCES ADDITION OF MULTI-MILLION DOLLAR ASSET VALUE WITH EQUITY STAKE IN MANIIN RESEARCH INC.

PR Newswire November 14, 2022

Q BIOMED PROVIDES SHAREHOLDER UPDATE

PR Newswire October 11, 2022

Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER

PR Newswire September 27, 2022

Traders News Source Senior Editor Mark Roberts Interviews Denis D Corin, CEO and Chairman Q BioMed Inc.

Accesswire August 25, 2022

Q BioMed Inc. Provides Update to Shareholders

PR Newswire July 29, 2022

Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer

PR Newswire July 26, 2022

Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets

PR Newswire May 6, 2022

Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer

PR Newswire March 16, 2022

Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market

PR Newswire March 7, 2022

Q BioMed Outlines Strategic Direction for 2022

PR Newswire February 14, 2022

Q BioMed Shows Significant Uptrend in Revenues in Year-End Update

PR Newswire December 16, 2021

Q BioMed Bolsters Commercialization of Strontium89 with EVERSANA Partnership

PR Newswire November 8, 2021

Q BioMed Inc. Provides Shareholder Update

PR Newswire October 25, 2021

Q BioMed Inc. Provides Update on Strontium89 Commercial Roll Out Revenue Up in 4th Quarter with Positive Trend

PR Newswire September 28, 2021

Q BioMed Inc. Updates on COVID-19 Therapeutic Development and Clinical Trials - MAN-19 therapeutic program heading to clinical trial in early 2022

PR Newswire September 22, 2021

Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent in South Korea and Shows Promising Results in Initial Pre-Clinical Testing

PR Newswire August 24, 2021

Q BioMed Signs Distribution Agreement with isoSolutions for the Sales of Strontium89 in Canada

PR Newswire August 10, 2021